Tranexamic acid to prevent OpeRation in Chronic subdural Hematoma (TORCH)

You likely can't join if

• potential subject who meets any of the following criteria is excluded from participation in this study: • Primary surgical treatment based on one or more of the following symptoms or parameters: medically intractable headache, midline shift >10mm (if >5mm, then judgement of second independent neurosurgeon is required), imminent death within 24 hours; • Structural causes for subdural haemorrhage, e.g. arachnoid cysts, cortical vascular malformations and a history of cranial surgery <1year; • Aneurysmal subarachnoid haemorrhage; • Active treatment for deep vein thrombosis, pulmonary embolism or cerebral thrombosis (secondary prophylaxis is not considered to be active treatment); • Active intravascular clotting or disseminated intravascular coagulation; • Known hypersensitivity or allergy to TXA or to any of the ingredients; • History of a blood coagulation disorder (hypercoagulability disorder); • History of severe impairment of renal function (serum creatinine >500μmol/L); • Anamnesis with signs of anaemia; • History of epilepsy; • History of inability to safely swallow oral medication. • Inability to obtain informed consent from the patient or legal representative (when the patient has a depressed level of consciousness as described in paragraph 11.2), including language barrier;